JP2012528830A - 少なくとも１つのアドレナリン作動性化合物を含む安定化された組成物 - Google Patents

少なくとも１つのアドレナリン作動性化合物を含む安定化された組成物 Download PDF

Info

Publication number
JP2012528830A
JP2012528830A JP2012513621A JP2012513621A JP2012528830A JP 2012528830 A JP2012528830 A JP 2012528830A JP 2012513621 A JP2012513621 A JP 2012513621A JP 2012513621 A JP2012513621 A JP 2012513621A JP 2012528830 A JP2012528830 A JP 2012528830A
Authority
JP
Japan
Prior art keywords
range
pharmaceutical composition
antioxidant
compound
sulfite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012513621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528830A5 (cg-RX-API-DMAC7.html
Inventor
ベイリー，アラン，ジェイ．
マクドナルド，ケネス
ポーティアス，パメラ
ヘンドリー，サイモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALK AG
Original Assignee
ALK AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALK AG filed Critical ALK AG
Publication of JP2012528830A publication Critical patent/JP2012528830A/ja
Publication of JP2012528830A5 publication Critical patent/JP2012528830A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012513621A 2009-06-04 2010-06-03 少なくとも１つのアドレナリン作動性化合物を含む安定化された組成物 Pending JP2012528830A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18406609P 2009-06-04 2009-06-04
DKPA200900705 2009-06-04
DKPA200900705 2009-06-04
US61/184,066 2009-06-04
PCT/EP2010/057771 WO2010139751A2 (en) 2009-06-04 2010-06-03 Stabilised composition comprising at least one adrenergic compound

Publications (2)

Publication Number Publication Date
JP2012528830A true JP2012528830A (ja) 2012-11-15
JP2012528830A5 JP2012528830A5 (cg-RX-API-DMAC7.html) 2013-07-11

Family

ID=41364279

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012513621A Pending JP2012528830A (ja) 2009-06-04 2010-06-03 少なくとも１つのアドレナリン作動性化合物を含む安定化された組成物
JP2012513622A Expired - Fee Related JP6087145B2 (ja) 2009-06-04 2010-06-03 少なくとも１つのアドレナリン作動性化合物を含む安定化された組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012513622A Expired - Fee Related JP6087145B2 (ja) 2009-06-04 2010-06-03 少なくとも１つのアドレナリン作動性化合物を含む安定化された組成物

Country Status (15)

Country Link
US (1) US9155694B2 (cg-RX-API-DMAC7.html)
EP (2) EP2437782B1 (cg-RX-API-DMAC7.html)
JP (2) JP2012528830A (cg-RX-API-DMAC7.html)
KR (2) KR20120044309A (cg-RX-API-DMAC7.html)
CN (3) CN102802668A (cg-RX-API-DMAC7.html)
AU (2) AU2010255747B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI1013019A2 (cg-RX-API-DMAC7.html)
CA (2) CA2764050C (cg-RX-API-DMAC7.html)
DK (2) DK2437781T3 (cg-RX-API-DMAC7.html)
ES (2) ES2432241T3 (cg-RX-API-DMAC7.html)
MX (2) MX2011012735A (cg-RX-API-DMAC7.html)
PT (2) PT2437782E (cg-RX-API-DMAC7.html)
RU (2) RU2527680C2 (cg-RX-API-DMAC7.html)
SI (2) SI2437782T1 (cg-RX-API-DMAC7.html)
WO (2) WO2010139752A2 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016050205A (ja) * 2014-08-28 2016-04-11 サン、ファーマスーティカル、インダストリーズ、リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． ノルエピネフリンの注射剤形
JP2017503017A (ja) * 2013-12-18 2017-01-26 ウィンドギャップ メディカル， インコーポレイテッド 薬物混合および送達システムならびに方法
JP2017506632A (ja) * 2014-02-27 2017-03-09 シンテティカ ソシエテ アノニム ノルアドレナリンの安定な低濃度の注射用溶液を生成するための方法
JP2017538731A (ja) * 2014-12-18 2017-12-28 ウィンドギャップ メディカル， インコーポレイテッド 治療剤を溶解または可溶化するための方法および組成物。
JP2020516688A (ja) * 2017-04-17 2020-06-11 ヒクマ・ファーマシューティカルズ・ユー・エス・エイ・インコーポレイテッド エピネフリンスプレー製剤
US12239822B2 (en) 2013-03-15 2025-03-04 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8628805B2 (en) * 2009-06-04 2014-01-14 Alk Ag Stabilized composition comprising at least one adrenergic compound
CN102525893B (zh) * 2012-01-04 2013-11-20 上海禾丰制药有限公司 盐酸去氧肾上腺素注射液及其制剂工艺
CN102525894A (zh) * 2012-01-04 2012-07-04 上海禾丰制药有限公司 盐酸异丙肾上腺素注射液及其制剂工艺
AU2013328393A1 (en) * 2012-10-08 2015-04-09 Wockhardt Limited Stable injectable pharmaceutical composition of epinephrine or salts thereof
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
KR20160070077A (ko) 2013-10-03 2016-06-17 임프리미스 파마슈티컬스 인코포레이티드 안구내 투여를 위한 에피네프린-기반 안과용 조성물 및 이의 제조 방법
CN103520096B (zh) * 2013-10-25 2015-02-25 成都晶博生物科技有限责任公司 一种硫酸特布他林注射液的生产工艺
KR20160104724A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
US9119876B1 (en) * 2015-03-13 2015-09-01 Par Pharmaceutical, Inc. Epinephrine formulations
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US11517525B2 (en) * 2015-09-18 2022-12-06 Hikma Pharmaceuticals Usa Inc. Epinephrine spray formulations
US10039710B2 (en) * 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
JP2019524896A (ja) 2016-08-25 2019-09-05 ハーロウ・ヘルス・インコーポレイテッドＨａｒｒｏｗ Ｈｅａｌｔｈ， Ｉｎｃ． 眼内投与のためのエピネフリンベースの眼科組成物及びその製造方法
RU2635759C1 (ru) * 2016-09-13 2017-11-15 Интеллег Сосьете Анониме Фармацевтическая композиция для парентерального введения и способ ее получения
US10835503B2 (en) * 2017-01-13 2020-11-17 Teva Pharmaceuticals Usa, Inc. Pre-filled syringe
US20250177328A1 (en) 2017-01-30 2025-06-05 Nevakar Injectables Inc. Norepinephrine compositions and methods therefor
WO2018140894A1 (en) 2017-01-30 2018-08-02 Nevakar, Inc Norepinephrine compositions and methods therefor
EP3687475A4 (en) * 2017-09-26 2021-07-28 YS Pharmtech STABILIZATION OF EPINEPHRIN FORMULATIONS
RU2020114880A (ru) 2017-10-10 2021-11-12 Мерк Патент Гмбх Стабилизированные инъекционные фармацевтические композиции l- эпинефрина
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3093725C (en) 2018-03-23 2021-08-24 Nevakar Inc. Epinephrine compositions and containers
US10952962B1 (en) 2018-04-11 2021-03-23 QuVa Pharma, Inc. Ready to use liquid formulation
WO2019200076A1 (en) 2018-04-11 2019-10-17 QuVa Pharma, Inc. Ready to use liquid reck formulation
US10478406B2 (en) 2019-03-18 2019-11-19 HARC Therapeutics AG High-pH solid-state epinephrine formulation
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
AU2020325831B2 (en) 2019-08-08 2025-09-25 Sun Pharmaceutical Industries Limited Infusion dosage form of norepinephrine
USD1004518S1 (en) 2019-09-09 2023-11-14 Brunswick Corporation Railing for a marine vessel
US12097170B2 (en) 2020-03-06 2024-09-24 Baxter International Inc. Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation
USD984953S1 (en) 2021-05-03 2023-05-02 Brunswick Corporation Safely railing having buoy holder
AU2021203856B2 (en) * 2021-06-10 2023-03-09 Animal Ethics Pty Ltd Topical anaesthetic composition having improved vasoconstrictor stability
AU2023332633A1 (en) * 2022-08-27 2025-04-03 Biophore India Pharmaceuticals Pvt. Ltd Trientine liquid dosage forms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033143A1 (ja) * 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
JP2005247866A (ja) * 1997-07-11 2005-09-15 Toray Ind Inc ４，５−エポキシモルヒナン誘導体を含有する安定な医薬品組成物
WO2007123800A2 (en) * 2006-04-03 2007-11-01 Nutramax Laboratories, Inc. Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them
JP2008522668A (ja) * 2004-12-06 2008-07-03 ワシントン バイオテック コーポレイション エピネフリンを送達するための方法および装置

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB425678A (en) 1933-06-15 1935-03-15 Novocol Chemical Mfg Co Inc Improvements relating to anesthetics for hypodermic injection
US2047144A (en) * 1934-03-26 1936-07-07 Lilly Co Eli Stabilized epinephrine-type compound, and process of stabilizing it
US2382546A (en) * 1941-11-03 1945-08-14 Curtis David Anesthetic solutions
BE617022A (cg-RX-API-DMAC7.html) 1961-04-28
US3419035A (en) * 1965-05-25 1968-12-31 Badger Meter Mfg Co Air elimination device for liquid transport system
CA981182A (en) 1972-01-07 1976-01-06 Walter A. Borisenok Stabilization of 1-epinephrine in local anesthetic solutions with a combination of three antioxidants
US3966905A (en) 1973-05-29 1976-06-29 Barnes-Hind Pharmaceuticals, Inc. Stabilized catechol amine solutions
DD150694A1 (de) 1980-04-16 1981-09-16 Gisela Raether Verfahren zur stabilisierung von pharmazeutischen praeparaten mit oxidationsempfindlichen bestandteilen
US4734438A (en) 1983-04-26 1988-03-29 Macri Frank J Norepinephrine potentiated compositions and method of use
AU5680994A (en) 1992-12-10 1994-07-04 Abbott Laboratories Stabilized catecholamine solutions
JP3535537B2 (ja) * 1993-04-15 2004-06-07 日本製薬株式会社 静脈注射剤
US6077545A (en) 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
DK0941085T3 (da) 1996-11-14 2003-08-11 Alza Corp Anordning til elektrisk hjulpet uddeling af stof, såsom lidocain og ephinephrin
JP4393641B2 (ja) 1998-11-26 2010-01-06 久光製薬株式会社 イオントフォレーシス用粘着ゲル組成物及びその装置
CA2424021A1 (en) 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine compositions and uses thereof
UA71839C2 (uk) 2003-12-30 2007-06-25 Товариство З Обмеженою Відповідальністю "Фарм-Стом" Фармацевтична композиція на основі артикаїну та епінефрину
US20050228336A1 (en) 2004-04-07 2005-10-13 Preston Keusch Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
US20070249727A1 (en) * 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US20080269347A1 (en) * 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
US8628805B2 (en) 2009-06-04 2014-01-14 Alk Ag Stabilized composition comprising at least one adrenergic compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005247866A (ja) * 1997-07-11 2005-09-15 Toray Ind Inc ４，５−エポキシモルヒナン誘導体を含有する安定な医薬品組成物
WO2005033143A1 (ja) * 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
JP2008522668A (ja) * 2004-12-06 2008-07-03 ワシントン バイオテック コーポレイション エピネフリンを送達するための方法および装置
WO2007123800A2 (en) * 2006-04-03 2007-11-01 Nutramax Laboratories, Inc. Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014026734; ボスミン（登録商標）注 第６版, 2007, ｐ．１-４ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12239822B2 (en) 2013-03-15 2025-03-04 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
JP2017503017A (ja) * 2013-12-18 2017-01-26 ウィンドギャップ メディカル， インコーポレイテッド 薬物混合および送達システムならびに方法
JP2023057163A (ja) * 2013-12-18 2023-04-20 ウィンドギャップ メディカル， インコーポレイテッド 薬物混合および送達システムならびに方法
US12239823B2 (en) 2013-12-18 2025-03-04 Windgap Medical, Inc. Drug mixing and delivery system and method
JP2017506632A (ja) * 2014-02-27 2017-03-09 シンテティカ ソシエテ アノニム ノルアドレナリンの安定な低濃度の注射用溶液を生成するための方法
JP2016050205A (ja) * 2014-08-28 2016-04-11 サン、ファーマスーティカル、インダストリーズ、リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． ノルエピネフリンの注射剤形
US11166923B2 (en) 2014-08-28 2021-11-09 Sun Pharmaceutical Industries Limited Parenteral dosage form of norepinephrine
JP2017538731A (ja) * 2014-12-18 2017-12-28 ウィンドギャップ メディカル， インコーポレイテッド 治療剤を溶解または可溶化するための方法および組成物。
US11246842B2 (en) 2014-12-18 2022-02-15 Windgap Medical, Inc. Method and compositions for dissolving or solubilizing therapeutic agents
JP2020516688A (ja) * 2017-04-17 2020-06-11 ヒクマ・ファーマシューティカルズ・ユー・エス・エイ・インコーポレイテッド エピネフリンスプレー製剤

Also Published As

Publication number Publication date
KR20120044309A (ko) 2012-05-07
JP6087145B2 (ja) 2017-03-01
WO2010139751A2 (en) 2010-12-09
CN102802668A (zh) 2012-11-28
EP2437781A2 (en) 2012-04-11
WO2010139751A3 (en) 2011-04-07
ES2432164T3 (es) 2013-12-02
EP2437782A2 (en) 2012-04-11
RU2527680C2 (ru) 2014-09-10
ES2432241T3 (es) 2013-12-02
DK2437782T3 (da) 2013-10-28
MX2011012735A (es) 2012-02-28
WO2010139752A3 (en) 2011-04-07
PT2437781E (pt) 2013-10-30
US20120129944A1 (en) 2012-05-24
SI2437781T1 (sl) 2013-12-31
AU2010255748A1 (en) 2011-12-08
WO2010139752A2 (en) 2010-12-09
MX2011012732A (es) 2012-02-28
AU2010255747B2 (en) 2014-03-13
CN106109397A (zh) 2016-11-16
RU2011153410A (ru) 2013-07-20
CA2764051A1 (en) 2010-12-09
CN102497882A (zh) 2012-06-13
AU2010255748B2 (en) 2014-03-13
PT2437782E (pt) 2013-10-30
EP2437782B1 (en) 2013-07-24
BRPI1013019A2 (pt) 2016-03-29
CA2764050A1 (en) 2010-12-09
SI2437782T1 (sl) 2013-12-31
US9155694B2 (en) 2015-10-13
BRPI1011074A2 (pt) 2016-04-12
CA2764050C (en) 2017-02-28
RU2011153403A (ru) 2013-07-20
AU2010255747A1 (en) 2012-02-02
KR20120028344A (ko) 2012-03-22
RU2527337C9 (ru) 2014-12-27
DK2437781T3 (da) 2013-10-21
RU2527337C2 (ru) 2014-08-27
EP2437781B1 (en) 2013-07-24
JP2012528831A (ja) 2012-11-15

Similar Documents

Publication Publication Date Title
JP6087145B2 (ja) 少なくとも１つのアドレナリン作動性化合物を含む安定化された組成物
US8628805B2 (en) Stabilized composition comprising at least one adrenergic compound
US12310930B2 (en) Stabilization of epinephrine formulations
US20180028671A1 (en) Epinephrine formulations for medicinal products
US12257342B2 (en) Phenylephrine hydrochloride ready-to-use solution
US20110015273A1 (en) Stable pharmaceutical aqueous compositions
HK1162976A1 (en) Stabilised composition comprising at least one adrenergic compound
HK1162976B (en) Stabilised composition comprising at least one adrenergic compound
HK1162975B (en) Stabilised composition comprising at least one adrenergic compound
CN118217243A (zh) 一种增效防腐且兼顾低刺激性的右美托咪定鼻喷剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140918

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150512